Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C27H50O6 |
| Molecular Weight | 470.6823 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC
InChI
InChIKey=VLPFTAMPNXLGLX-UHFFFAOYSA-N
InChI=1S/C27H50O6/c1-4-7-10-13-16-19-25(28)31-22-24(33-27(30)21-18-15-12-9-6-3)23-32-26(29)20-17-14-11-8-5-2/h24H,4-23H2,1-3H3
| Molecular Formula | C27H50O6 |
| Molecular Weight | 470.6823 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: http://www.about-axona.com/assets/files/us-en/global/pdf/Axona-PrescribingInformation.pdfCurator's Comment: Description was created based on several sources, including https://www.drugs.com/cdi/axona.html and https://www.ncbi.nlm.nih.gov/pubmed/19664276
Sources: http://www.about-axona.com/assets/files/us-en/global/pdf/Axona-PrescribingInformation.pdf
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/cdi/axona.html and https://www.ncbi.nlm.nih.gov/pubmed/19664276
Tricaprylin is a triester of glycerin and caprylic acid. It is used as a fragrance ingredient, solvent, and primarily as an emollient in a variety of personal care products, including makeup, creams and lotions, deodorants, sunscreens, hair conditioners, and skin cleansers. Tricaprylin is an ingredient of Axona, a prescription medical food intended for the clinical dietary management of the metabolic processes associated with mild to moderate Alzheimer’s disease. Axona provides a simple and safe method to induce hyperketonemia, thus providing an alternative energy substrate to glucose in the brain of patients with AD. After oral administration of Axona, Tricaprylin in Axona is processed by enzymes in the gut, and the resulting medium-chain fatty acids (MCFAs) are absorbed into the blood supply leading to the liver. The MCFAs rapidly pass directly to the liver, where they undergo oxidation to form ketones. Since the liver does not use ketones, they are released into the circulation to be used by nonliver tissues. Some ketones can cross the blood-brain barrier and are then taken up by brain cells. While glucose is the brain’s chief energy source, ketones normally serve as the "backup" energy source. Ketones the body produces after Axona is consumed, act as an alternative energy source for brain cells that have lost their ability to use glucose (sugar) as a result of Alzheimer’s disease.
CNS Activity
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Blood D-(-)-3-hydroxybutyrate concentrations after oral administration of trioctanoin, trinonanoin, or tridecanoin to newborn rhesus monkeys (Macaca mulatta). | 2010-12 |
|
| Influence of cyclosporine A on molecular interactions in lyotropic reverse hexagonal liquid crystals. | 2010-10-14 |
|
| Biochemical characterization and mutational improvement of a thermophilic esterase from Sulfolobus solfataricus P2. | 2010-08 |
|
| Pulmonary modulation of benzo[a]pyrene-induced hemato- and hepatotoxicity in broilers. | 2010-07 |
|
| Should the ApoE genotype be a covariate for clinical trials in Alzheimer disease? | 2010-06-08 |
|
| Lysozyme entrapped within reverse hexagonal mesophases: physical properties and structural behavior. | 2010-01-01 |
|
| Structural rearrangements and interaction within H(II) mesophase induced by cosolubilization of vitamin E and ascorbic acid. | 2009-11-17 |
|
| Fatty acid selectivity of lipases during acidolysis reaction between oleic acid and monoacid triacylglycerols. | 2009-11-11 |
|
| Achievements and new knowledge unraveled by metagenomic approaches. | 2009-11 |
|
| Thermostable lipases from the extreme thermophilic anaerobic bacteria Thermoanaerobacter thermohydrosulfuricus SOL1 and Caldanaerobacter subterraneus subsp. tengcongensis. | 2009-09 |
|
| Lipase-catalyzed reactions at interfaces of two-phase systems and microemulsions. | 2009-09 |
|
| Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. | 2009-08-10 |
|
| Effect of octanoic acid-rich formula on plasma ghrelin levels in cachectic patients with chronic respiratory disease. | 2009-06-16 |
|
| Molecular dynamics simulations of functional group effects on solvation thermodynamics of model solutes in decane and tricaprylin. | 2009-05-13 |
|
| Modeling kinetics of subcellular disposition of chemicals. | 2009-05 |
|
| Molecular interactions in reverse hexagonal mesophase in the presence of Cyclosporin A. | 2009-02-09 |
|
| Identifying efficacious approaches to chemoprevention with chlorophyllin, purified chlorophylls and freeze-dried spinach in a mouse model of transplacental carcinogenesis. | 2009-02 |
|
| Cloning and characterization of a new cold-active lipase from a deep-sea sediment metagenome. | 2009-01 |
|
| Effects of cytochrome p450 inhibitors on itraconazole and fluconazole induced cytotoxicity in hepatocytes. | 2009 |
|
| Distinction between esterases and lipases: comparative biochemical properties of sequence-related carboxylesterases. | 2009 |
|
| Esterification and hydrolytic activities of Candida rugosa lipase isoform 1 (LIP1) immobilized on celite 545, duolite A7, and sephadex G-25. | 2008-11-12 |
|
| Solubilization of nutraceuticals into reverse hexagonal mesophases. | 2008-08-21 |
|
| Competition between lipases and monoglycerides at interfaces. | 2008-07-15 |
|
| Action of Humicola lanuginosa lipase on mixed monomolecular films of tricaprylin and polyethylene glycol stearate. | 2008-05-01 |
|
| Quantitative solubility relationships and the effect of water uptake in triglyceride/monoglyceride microemulsions. | 2008-05 |
|
| Low viscosity reversed hexagonal mesophases induced by hydrophilic additives. | 2008-04-03 |
|
| Vehicle-dependent disposition kinetics of fluoranthene in Fisher-344 rats. | 2008-03 |
|
| A comparative study on two fungal lipases from Thermomyces lanuginosus and Yarrowia lipolytica shows the combined effects of detergents and pH on lipase adsorption and activity. | 2007-12 |
|
| Isolation of lipase producing Bacillus sp. from olive mill wastewater and improving its enzyme activity. | 2007-11-19 |
|
| An HII liquid crystal-based delivery system for cyclosporin A: physical characterization. | 2007-04-15 |
|
| [Microstructure of novel solid lipid nanoparticle loaded triptolide]. | 2007-04 |
|
| Kinetic model of 1,3-specific triacylglycerols alcoholysis catalyzed by lipases. | 2007-01-20 |
|
| Effects of protein composition and enzymatic activity on formation and properties of potato protein stabilized emulsions. | 2006-08-23 |
|
| Stability of triglyceride liquid films on hydrophilic and hydrophobic glasses. | 2006-07-01 |
|
| Val-407 and Ile-408 in the beta5'-loop of pancreatic lipase mediate lipase-colipase interactions in the presence of bile salt micelles. | 2006-03-24 |
|
| Technological properties of Enterococcus faecium isolated from ewe's milk and cheese with importance for flavour development. | 2006-03 |
|
| Lymphatic transport of a physical mixture of medium- and long-chain TAG in rats. | 2006-01 |
|
| Secretion of pro- and mature Rhizopus arrhizus lipases by Pichia pastoris and properties of the proteins. | 2006-01 |
|
| Substrate specificity and kinetic properties of enzymes belonging to the hormone-sensitive lipase family: comparison with non-lipolytic and lipolytic carboxylesterases. | 2005-12-30 |
|
| Topical absorption of piroxicam from organogels--in vitro and in vivo correlations. | 2005-07-14 |
|
| Transitions induced by solubilized fat into reverse hexagonal mesophases. | 2005-06-25 |
|
| Tricaprylin microemulsion for oral delivery of low molecular weight heparin conjugates. | 2005-06-20 |
|
| Mutations in the "lid" region affect chain length specificity and thermostability of a Pseudomonas fragi lipase. | 2005-04-25 |
|
| Dialkylphosphatidylcholine and egg yolk lecithin for emulsification of various triglycerides. | 2005-04-10 |
|
| Might the kinetic behavior of hormone-sensitive lipase reflect the absence of the lid domain? | 2004-07-27 |
|
| Structural characterisation of water-Tween 40/Imwitor 308-isopropyl myristate microemulsions using different experimental methods. | 2004-05-19 |
|
| On the calculation of disjoining pressure isotherms for nonaqueous films. | 2004-02-15 |
|
| [Effect of triester glycerol type of plasticizers on release of albumin from biodegradable polymer matrices]. | 2004-01 |
|
| Quantitative evaluation of reconstruction methods after gastrectomy using a new type of examination: digestion and absorption test with stable isotope 13C-labeled lipid compound. | 2003 |
|
| Interstrain differences in susceptibility to liver carcinogenesis initiated by N-nitrosodiethylamine and its promotion by phenobarbital in C57BL/6NCr, C3H/HeNCrMTV- and DBA/2NCr mice. | 1986-02 |
Patents
Sample Use Guides
Axona is taken orally once a day shortly after a full meal. Patients should start with a graduated dosing regimen for 7 days, or as directed by the supervising healthcare provider, before taking one full packet (40 grams) per day. Axona should be added to 4 to 8 ounces (118 to 236 milliliters) of water or other liquids, and shaken or blended until fully mixed. Axona consists primarily of a proprietary formulation of >95% pure semisynthetic caprylic triglyceride (Tricaprylin). Each 40g packet contains 20 g of Tricaprylin
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:09:20 GMT 2025
by
admin
on
Mon Mar 31 18:09:20 GMT 2025
|
| Record UNII |
6P92858988
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
777020
Created by
admin on Mon Mar 31 18:09:20 GMT 2025 , Edited by admin on Mon Mar 31 18:09:20 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
AXONA
Created by
admin on Mon Mar 31 18:09:20 GMT 2025 , Edited by admin on Mon Mar 31 18:09:20 GMT 2025
|
PRIMARY | |||
|
7829
Created by
admin on Mon Mar 31 18:09:20 GMT 2025 , Edited by admin on Mon Mar 31 18:09:20 GMT 2025
|
PRIMARY | |||
|
208-686-5
Created by
admin on Mon Mar 31 18:09:20 GMT 2025 , Edited by admin on Mon Mar 31 18:09:20 GMT 2025
|
PRIMARY | |||
|
4059
Created by
admin on Mon Mar 31 18:09:20 GMT 2025 , Edited by admin on Mon Mar 31 18:09:20 GMT 2025
|
PRIMARY | |||
|
DTXSID6021375
Created by
admin on Mon Mar 31 18:09:20 GMT 2025 , Edited by admin on Mon Mar 31 18:09:20 GMT 2025
|
PRIMARY | |||
|
10584
Created by
admin on Mon Mar 31 18:09:20 GMT 2025 , Edited by admin on Mon Mar 31 18:09:20 GMT 2025
|
PRIMARY | |||
|
SUB126762
Created by
admin on Mon Mar 31 18:09:20 GMT 2025 , Edited by admin on Mon Mar 31 18:09:20 GMT 2025
|
PRIMARY | |||
|
1314420
Created by
admin on Mon Mar 31 18:09:20 GMT 2025 , Edited by admin on Mon Mar 31 18:09:20 GMT 2025
|
PRIMARY | RxNorm | ||
|
6P92858988
Created by
admin on Mon Mar 31 18:09:20 GMT 2025 , Edited by admin on Mon Mar 31 18:09:20 GMT 2025
|
PRIMARY | |||
|
10850
Created by
admin on Mon Mar 31 18:09:20 GMT 2025 , Edited by admin on Mon Mar 31 18:09:20 GMT 2025
|
PRIMARY | |||
|
DB12176
Created by
admin on Mon Mar 31 18:09:20 GMT 2025 , Edited by admin on Mon Mar 31 18:09:20 GMT 2025
|
PRIMARY | |||
|
6P92858988
Created by
admin on Mon Mar 31 18:09:20 GMT 2025 , Edited by admin on Mon Mar 31 18:09:20 GMT 2025
|
PRIMARY | |||
|
538-23-8
Created by
admin on Mon Mar 31 18:09:20 GMT 2025 , Edited by admin on Mon Mar 31 18:09:20 GMT 2025
|
PRIMARY | |||
|
CHEMBL1406148
Created by
admin on Mon Mar 31 18:09:20 GMT 2025 , Edited by admin on Mon Mar 31 18:09:20 GMT 2025
|
PRIMARY | |||
|
FG-180
Created by
admin on Mon Mar 31 18:09:20 GMT 2025 , Edited by admin on Mon Mar 31 18:09:20 GMT 2025
|
PRIMARY | |||
|
1295797
Created by
admin on Mon Mar 31 18:09:20 GMT 2025 , Edited by admin on Mon Mar 31 18:09:20 GMT 2025
|
PRIMARY | |||
|
76978
Created by
admin on Mon Mar 31 18:09:20 GMT 2025 , Edited by admin on Mon Mar 31 18:09:20 GMT 2025
|
PRIMARY | |||
|
C45678
Created by
admin on Mon Mar 31 18:09:20 GMT 2025 , Edited by admin on Mon Mar 31 18:09:20 GMT 2025
|
CONCEPT | Industrial Aid | ||
|
C29861
Created by
admin on Mon Mar 31 18:09:20 GMT 2025 , Edited by admin on Mon Mar 31 18:09:20 GMT 2025
|
PRIMARY | |||
|
100000152983
Created by
admin on Mon Mar 31 18:09:20 GMT 2025 , Edited by admin on Mon Mar 31 18:09:20 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
LABELED -> NON-LABELED |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|